Use of Alfentanil in Palliative Care.
alfentanil
pain relief
palliative care
renal impairment
Journal
Pharmacy (Basel, Switzerland)
ISSN: 2226-4787
Titre abrégé: Pharmacy (Basel)
Pays: Switzerland
ID NLM: 101678532
Informations de publication
Date de publication:
16 Dec 2020
16 Dec 2020
Historique:
received:
28
10
2020
revised:
16
11
2020
accepted:
20
11
2020
entrez:
19
12
2020
pubmed:
20
12
2020
medline:
20
12
2020
Statut:
epublish
Résumé
Alfentanil is used for chronic pain relief in palliative care. However, there is a dearth of data on its use. For this reason, a decision was made to review the use of alfentanil in palliative care. Retrospective study was carried out in a palliative care service. The files of patients who received alfentanil as an intravenous or subcutaneous continuous infusion for pain relief, between January 2018 and April 2019. In total, 111 patients received alfentanil out of 113 admissions. Of them, 56 were male, and the median age was 70 years. The median number of days on alfentanil was 6 (range 1 to 129). The most frequent primary reasons for switching to alfentanil was uncontrolled pain in 52 (46%) patients and renal impairment in 24 (21%) patients. The median 24-h initial dose of alfentanil was 4 mg (1-20), and the median final 24-h dose of alfentanil was 5 mg (1-60), (
Identifiants
pubmed: 33339325
pii: pharmacy8040240
doi: 10.3390/pharmacy8040240
pmc: PMC7768509
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 1995 May 6;345(8958):1185
pubmed: 7536877
Anesth Analg. 2000 Jul;91(1):110-6
pubmed: 10866896
Drug Intell Clin Pharm. 1986 May;20(5):335-41
pubmed: 3086065
Clin Pharmacokinet. 2007;46(8):681-96
pubmed: 17655375
Am J Emerg Med. 2017 Oct;35(10):1451-1456
pubmed: 28438447
Palliat Med. 2004 Sep;18(6):516-9
pubmed: 15453622
BMJ Support Palliat Care. 2017 Sep;7(3):265-266
pubmed: 28347998
Palliat Med. 2011 Jul;25(5):525-52
pubmed: 21708859
J Pain Res. 2018 Oct 29;11:2587-2601
pubmed: 30464578
Cancer. 2007 Sep 15;110(6):1376-84
pubmed: 17634949